Daraxonrasib (Rasonque), recently approved for the treatment of metastatic pancreatic cancer, is also showing promise in the treatment of lung cancer in early trials.

CLEVELAND, Ohio — When we hear that a friend has breast cancer, we know they’re in for a rough patch but will probably be fine in the end. The reaction is very different if the diagnosis is aggressive ...

AstraZeneca’s equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings ...

A new experimental drug called CS18 may help break through cancer drug resistance by disabling several of the defenses tumors ...

Because most women with HR-positive breast cancer are advised to avoid hormone therapy, a nonhormonal option matters. The FDA ...

How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages Northwestern University economist ...

The British drugs company has ploughed £1.5bn into US pharma firm Summit Therapeutics as part of a cancer treatment research ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

A UCLA study of more than 14,000 patient-drug pairs finds insurers and patients paid less for biosimilars than for brand-name biologics.

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this ...

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, will invest $2 billion in Summit Therapeutics Inc ...